hackint0sh/New-Dataset huggingface dataset:
Participants will complete a four-week well-being program and complete surveys via an app on their phone. Participants can expect to participate in the study for four months. conditions: Depression conditions: Anxiety conditions: Depression/Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 460 type: ESTIMATED name: HMP app name: HMRP web app measure: Change in Composite of Patient-Reported Outcomes Measurement Information System (PROMIS) Depression and PROMIS Anxiety measure: HMP App Utilization: Days measure: HMP App Utilization: Number of Activities measure: HMP App Utilization: Minutes measure: Change in Healthy Minds Index (HM Index): Awareness measure: Change in Healthy Minds Index (HM Index): Connection measure: Change in Healthy Minds Index (HM Index): Purpose measure: Change in Healthy Minds Index (HM Index): Insight measure: Change in Subjective Happiness Scale measure: Change in Satisfaction with Life Scale (SWLS) measure: Change in Perceived Stress Scale (PSS-10) measure: Change in Flourishing Measure measure: Change in Digital Working Alliance Inventory (DWAI) measure: Change in Experiences Questionnaire (EQ) Decentering Subscale measure: Change in Five Facet Mindfulness Questionnaire (FFMQ) Awareness Subscale measure: Change in NIH Toolbox Loneliness measure: Change in Wellbeing Growth Mindset measure: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Meaning and Purpose sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Wisconsin city: Madison state: Wisconsin zip: 53705 country: United States name: Simon Goldberg, PhD role: CONTACT phone: 608-265-8986 email: sbgoldberg@wisc.edu name: Simon Goldberg, PhD role: PRINCIPAL_INVESTIGATOR lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06282510 id: 23053003 briefTitle: Nasal Antisepsis for C. Auris Prevention overallStatus: RECRUITING date: 2024-01-29 date: 2026-12 date: 2028-12 date: 2024-02-28 date: 2024-02-28 name: Mary K Hayden class: OTHER name: Rush University Medical Center name: RML Specialty Hospital briefSummary: This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris. conditions: Candida Auris Infection conditions: Colonization, Asymptomatic studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Povidone Iodine Topical measure: Detection of C. auris from the anterior nares measure: Detection of C. auris from body sites other than anterior nares measure: Detection of C. auris from environmental surfaces measure: Detection of methicillin-resistant Staphylococcus aureus (MRSA) from body sites other than anterior nares measure: Detection of MRSA from environmental surfaces measure: Non-susceptibility of C. auris to povidone iodine measure: Change in microbiome community sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rush University Medical Center status: RECRUITING city: Chicago state: Illinois zip: 60612 country: United States name: Sarah E Sansom, DO role: CONTACT phone: 312-563-6201 email: sarah_e_sansom@rush.edu name: Mary K Hayden, MD role: CONTACT phone: 312-942-8727 email: mhayden@rush.edu lat: 41.85003 lon: -87.65005 facility: RML Specialty Hospital status: RECRUITING city: Chicago state: Illinois zip: 60624 country: United States name: Nidhi Undevia, MD role: CONTACT phone: 630-286-4000 email: nundevia@rmlspecialtyhospital.org name: Lisa Duffner role: CONTACT phone: 630-286-4000 email: LMikolajewski@rmlspecialtyhospital.org lat: 41.85003 lon: -87.65005 facility: RML Specialty Hospital status: RECRUITING city: Hinsdale state: Illinois zip: 60521 country: United States name: Nidhi Undevia, MD role: CONTACT phone: 630-286-4000 email: nundevia@rmlspecialtyhospital.org name: Lisa Duffner role: CONTACT phone: (630) 286-4000 email: LMikolajewski@rmlspecialtyhospital.org lat: 41.80086 lon: -87.93701 hasResults: False
nctId: NCT06282497 id: ZSCPH-003 briefTitle: Xerostomia-optimised IMRT Versus Standard IMRT in NPC overallStatus: RECRUITING date: 2023-10-23 date: 2026-10-23 date: 2029-10-23 date: 2024-02-28 date: 2024-02-28 name: Zhongshan People's Hospital, Guangdong, China class: OTHER briefSummary: This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of xerostomia-optimized intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in NPC patients conditions: Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 524 type: ESTIMATED name: Optimised neck CTV name: standard neck CTV measure: Regional recurrence free survival measure: Overall survival measure: Local recurrence free survival measure: Distant metastasis-free survival measure: Progression free survival measure: Acute toxicities measure: Late toxicities sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhongshan City People's Hospital status: RECRUITING city: Zhongshan state: Guangdong zip: 528403 country: China name: Gui-qiong Xu, MD role: CONTACT phone: +8613528109888 email: donna_shee@163.com lat: 21.31992 lon: 110.5723 hasResults: False
nctId: NCT06282484 id: KY20232348-C-1 briefTitle: A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions overallStatus: COMPLETED date: 2022-09-01 date: 2023-06-01 date: 2023-09-29 date: 2024-02-28 date: 2024-02-28 name: Xijing Hospital of Digestive Diseases class: OTHER briefSummary: To explore the effects of gastric xanthoma on gastric cancer and its precancerous lesions, so as to better prevent the occurrence and development of gastric cancer. conditions: Gastric Xanthoma conditions: Helicobacter Pylori Infection conditions: Gastric Cancer conditions: Intestinal Metaplasia conditions: Precancerous Lesions studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 1260 type: ACTUAL measure: corelation between the gastric xanthoma and gastric mucosa diseases sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xijing Hosipital of Digestive Disease city: Xi'an state: Shaanxi zip: 710032 country: China lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06282471 id: MCC-23-20794 id: HM20028614 type: OTHER domain: Virginia Commonwealth University briefTitle: EW and Self-Guided PST in Cancer Survivors and Caregivers overallStatus: RECRUITING date: 2024-02-21 date: 2026-03-31 date: 2026-03-31 date: 2024-02-28 date: 2024-02-29 name: Virginia Commonwealth University class: OTHER briefSummary: To assess the feasibility and acceptability of expressive writing + problem solving therapy (EW+PST) among cancer survivors and informal caregivers conditions: Cancer Survivors conditions: Informal Caregivers studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 50 type: ESTIMATED name: Expressive Writing and Problem-Solving Therapy (EW+PST) measure: Consent Rate measure: Study Retention measure: Completed Journal Entries measure: Patient Satisfaction Questionnaire measure: Change in Post Traumatic Growth Inventory (PTGI) Score from 0 to 6 weeks measure: Change in European Organization for the Research and Treatment of Life Questionnaire (EORTC QLQ-30) Score from 0 to 6 weeks measure: Change in Patient Health Questionnaire-8 (PHQ-8) Score from 0 to 6 Weeks measure: Change in Perceived Stress Scale-10 item (PSS-10) Score from 0 to 6 Weeks measure: Change in New General Self-Efficacy Scale (GSES-N) Score from 0 to 6 Weeks measure: Change in Multidimensional Scale of Perceived Social Support (MSPSS) Score from 0 to 6 Weeks measure: Change in Family Environment Scale-Revised (FES-R) Score from 0 to 6 Weeks measure: Change in Cancer Communication Assessment Tool for Patients and Families (CCAT-PF) Score from 0 to 6 Weeks measure: Change in Caregiver Burden Scale (CBS) Score from 0 to 6 Weeks measure: Change in EORTC Quality of Life Core Scale (EORTC QLQ-30) Score from 0 to 6 Weeks sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Virginia Commonwealth University status: RECRUITING city: Richmond state: Virginia zip: 23298 country: United States name: Kendra Rowe role: CONTACT phone: 804-828-1965 email: rowek2@vcu.edu name: Massey CPC Team role: CONTACT phone: 804-828-1965 email: MasseyCPC@vcu.edu name: Susan Hong, MD role: PRINCIPAL_INVESTIGATOR lat: 37.55376 lon: -77.46026 hasResults: False
nctId: NCT06282458 id: V2000101 briefTitle: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2024-12-20 date: 2025-04-30 date: 2024-02-28 date: 2024-04-24 name: Veru Inc. class: INDUSTRY briefSummary: The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists. conditions: Muscle Loss conditions: Obesity studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Subjects will be randomized to the three treatment arms (GLP-1 receptor agonist plus either enobosarm 3mg dose group, enobosarm 6mg dose group, or placebo group) in a 1:1:1 fashion. All patients randomized into this study will be medically indicated for use of GLP-1 receptor agonist for weight management. NOTE: First dose of GLP-1 receptor agonist will be Day 1 of this study.
nctId: NCT06282445 id: K2024035 briefTitle: Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer overallStatus: RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2026-03-31 date: 2024-02-28 date: 2024-02-28 name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine class: OTHER briefSummary: To evaluate the efficacy and safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer. conditions: Colorectal Cancer Metastatic studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: Adebrelimab name: Oxaliplatin name: Capecitabine name: Bevacizumab measure: Progression-free survival measure: Organ retention rate measure: Overall survival measure: Disease Control Rate measure: Surgical conversion rate measure: TRAEs sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Fourth Affiliated Hospital Zhejiang University School of Medicine status: RECRUITING city: Jinhua state: Zhejiang zip: 322000 country: China name: Qijia Xuan, MD&Phd role: CONTACT lat: 29.10678 lon: 119.64421 hasResults: False
nctId: NCT06282432 id: RP-L201-0121-LTFU briefTitle: Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) overallStatus: ENROLLING_BY_INVITATION date: 2022-03-09 date: 2037-03 date: 2037-03 date: 2024-02-28 date: 2024-02-28 name: Rocket Pharmaceuticals Inc. class: INDUSTRY briefSummary: This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene conditions: Leukocyte Adhesion Deficiency studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 9 type: ESTIMATED measure: Hematopoietic stem cell transplant (HSCT) free survival measure: Incidence of hospitalizations measure: Incidence of significant infections measure: Resolution of LAD-I-related skin rash measure: Resolution of LAD-I-related periodontal abnormalities measure: Event free survival measure: Overall Survival measure: Long-term genetic correction in peripheral blood mononuclear cells (PBMCs) measure: Long-term genetic correction in PB CD15+ granulocytes measure: Long-term CD18 neutrophil expression by flow cytometry measure: Long-term CD11 neutrophil expression by flow cytometry measure: Improvement or resolution of LAD-I related neutrophilia measure: Improvement or resolution of LAD-I-related leukocytosis. measure: Incidence of Investigational Product (IP) related serious adverse events (SAEs) measure: Incidence of hematologic malignancy sex: ALL minimumAge: 3 Months stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of California, Los Angeles (UCLA) city: Los Angeles state: California zip: 90095-1489 country: United States lat: 34.05223 lon: -118.24368 facility: Hospital Infantil Universitario Niño Jesús city: Madrid zip: 28009 country: Spain lat: 40.4165 lon: -3.70256 facility: University College London Great Ormond Street Institute of Child Health (GOSH) city: London zip: WC1N 1EH country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06282419 id: B.30.2.ATA.0.01.00/542 briefTitle: The Effect of Visual and Audio Stimulus Offered to Father-to-be overallStatus: RECRUITING date: 2023-08-21 date: 2024-03-31 date: 2025-12-31 date: 2024-02-28 date: 2024-03-01 name: Ataturk University class: OTHER briefSummary: It was aimed to evaluate the effect of visual and auditory stimuli presented to father candidates on postpartum breastfeeding success of mothers, perception of spousal support and postpartum depression. The study, which was carried out in a randomized controlled experimental design, consists of nulliparous pregnant women and their spouses who came to the relevant health center for prenatal control between May 2023 and May 2024. In the study, 132 pregnant women (Experimental group 1:44, Experimental group 2:44, control group:44) were recruited with a priori power analysis. In the study, women and their spouses were assigned to the experimental and control groups by randomization. For randomization, single-group columns between 1-165 were created in the system using the Random Integer Generator method in the Numbers subheading of the random.org website. Considering the numbers 1, 2 and 3 in the column, nulliparous pregnant women coming to the polyclinic were randomly assigned to these numbers. Which numbers constitute which group was determined by drawing lots at the beginning of the research. In data collection, Introductory Information Form for women, Women's Perceived Spousal Support Scale in Early Postpartum Process, Breastfeeding Self-Efficacy Scale-Short Form, Breastfeeding Adaptation Scale and Edinburgh Postpartum Depression Scale; Introductory Information Form for men, Fathers; Breastfeeding Attitude and Participation Scale and Edinburgh Postpartum Depression Scale (for Men) were used. Data; It was evaluated in the SPSS program. conditions: Ultrasonography Prenatal studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a study that evaluates the effects on mothers by involving fathers in the pregnancy follow-up process through the use of mobile ultrasound. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 132 type: ESTIMATED name: USE OF MOBILE ULTRASOUND name: ultrasound image taken from the internet measure: Introductory Information Form (For Women) measure: Spouse Support Scale Perceived by Women During Early Postpartum Period measure: Breastfeeding Self-Efficacy Scale-Short Form measure: Breastfeeding Adaptation Scale measure: Edinburgh Postpartum Depression Scale measure: Introductory Information Form (For Men) measure: Fathers' Breastfeeding Attitude and Participation Scale measure: Edinburgh Postpartum Depression Scale for Men sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Atatürk University status: RECRUITING city: Erzurum country: Turkey name: Merve Çakıl role: CONTACT phone: +905310854245 email: mervecakil92@gmail.com name: Ayla KANBUR role: CONTACT email: aylakanbur28@hotmail.com lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06282406 id: N4532-R id: I0X1RX004532 type: OTHER_GRANT domain: U.S. Department of Veterans Affairs briefTitle: Pupil-Indexed Noninvasive Neuromodulation overallStatus: NOT_YET_RECRUITING date: 2024-06-03 date: 2028-04-03 date: 2028-08-05 date: 2024-02-28 date: 2024-02-28 name: VA Office of Research and Development class: FED briefSummary: Vagus nerve stimulation (VNS) is thought to activate neural pathways that release chemicals which promote plasticity and learning. Previous work has shown that the auricular branch of the vagus nerve innervates landmarks on the external ear. Work from the PI's laboratory has shown that electrical current applied to the external ear modulates physiological indexes of brain states implicated in the therapeutic effects of VNS. The broad objective of this project is to better understand physiological mechanisms modulated by auricular stimulation to support possible therapeutic effects in the form of motor learning. conditions: Paresis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Subjects will be randomized into one of 5 groups and receive the designated stimulation/sham during a training protocol designed to facilitate motor learning. primaryPurpose: TREATMENT masking: NONE count: 110 type: ESTIMATED name: Transcutaneous Electrical Stimulation name: Sham measure: Force Control Change sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA city: Pittsburgh state: Pennsylvania zip: 15240 country: United States name: Elizabeth B Toth, BA role: CONTACT phone: 412-954-5382 email: elizabeth.toth2@va.gov name: Kimberly A Toland role: CONTACT phone: (412) 215-5084 email: Kimberly.Toland@va.gov name: Michael A. Urbin, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.44062 lon: -79.99589 hasResults: False
nctId: NCT06282393 id: Z-2023072 briefTitle: FibriCheck Data Registry acronym: FDR overallStatus: RECRUITING date: 2024-01-31 date: 2026-02 date: 2026-03 date: 2024-02-28 date: 2024-02-28 name: Qompium NV class: INDUSTRY briefSummary: The goal of this interventional clinical trial is to establish a comprehensive, structured database that includes photoplethysmography (PPG) measurements with simultaneously recorded electrocardiography (ECG) data to evaluate the FibriCheck Algorithm in patients with heart rhythm disorders. conditions: Cardiac Arrhythmia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 150 type: ESTIMATED name: FibriCheck recordings measure: Alignment PPG measurement sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ziekenhuis Oost Limburg status: RECRUITING city: Genk state: Limburg zip: 3600 country: Belgium name: Pieter Vandervoort, MD role: CONTACT phone: 089/325050 email: pieter.vandervoort@zol.be lat: 50.965 lon: 5.50082 hasResults: False
nctId: NCT06282380 id: FDA-AF study briefTitle: Fibricheck Detection cApabilities for Atrial Fibrillation acronym: FDA-AF overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-05 date: 2024-05 date: 2024-02-28 date: 2024-02-28 name: Qompium NV class: INDUSTRY briefSummary: Evaluation of accuracy of the FibriCheck Mobile Application on various smartphone devices, compared to the reference diagnosis. conditions: Atrial Fibrillation studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 250 type: ESTIMATED name: FibriCheck Mobile Application measure: Accuracy of the FibriCheck Mobile Application measure: Sensitivity of the FibriCheck Mobile Application measure: Specificity of the FibriCheck Mobile Application sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06282367 id: JOSE AGURTO TELLO HOSPITAL briefTitle: Bowel Preparation for Colonoscopy With Oral Lactulose overallStatus: COMPLETED date: 2021-07-01 date: 2023-04-01 date: 2023-04-01 date: 2024-02-28 date: 2024-02-28 name: Josue Aliaga class: OTHER_GOV briefSummary: Background and Aims: The quality of colonoscopy is critically influenced by bowel preparation. Polyethylene glycol (PEG) is considered the gold standard regimen for bowel preparation, however due to the necessity of large volume of patient's tolerance is impaired, especially in the elderly population. Lactulose has been adopted in a few centers as a novel alternative for colonoscopy preparation. This study aimed to investigate the efficacy-safety profile of a lactulose-based bowel preparation in comparison to PEG for colonoscopy.
Methods: Prospective non-blinded comparative study, developed in two tertiary centers from July 2021 to April 2023. Outpatients undergoing colonoscopy were randomly divided into 2 groups: Group 1 (111 patients): PEG and Group 2 (111 patients): Lactulose. The following clinical outcomes were assessed for each group: degree of bowel clearance using the Boston Score, colorectal polyp detection rate, adenoma detection rate, tolerability and side effects. conditions: Colonoscopy conditions: Colonoscopy Preparation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 222 type: ACTUAL measure: Degree of bowel cleansing using the Boston score measure: adenomas detection rate sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jose Agurto Tello Hospital city: Lima zip: 05001 country: Peru lat: -12.04318 lon: -77.02824 hasResults: False
nctId: NCT06282354 id: NP4035/2023 briefTitle: Telemedicine for Postoperative Follow-up After Oncological Surgeries overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-08-15 date: 2025-02-15 date: 2024-02-28 date: 2024-02-28 name: Instituto do Cancer do Estado de São Paulo class: OTHER briefSummary: The study will be a prospective, randomized, non-inferiority, open-label study, to be carried out at the Cancer Institute of the State of São Paulo for 6 months and will include patients agreeing to voluntary participation upon signing an informed consent form. conditions: Urologic Cancer conditions: Satisfaction, Patient conditions: Surgery conditions: Postoperative Adhesion studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Type of post-operative appointment measure: Patient satisfaction in the post-operative return measure: unattended arrivals at the institution measure: Postoperative complications measure: Appointment's time measure: Number of exams requested measure: Total cost involved per service measure: Environmental impact sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False